Heron Theraps Inc Drug Patent Portfolio

Heron Theraps Inc owns 4 orange book drugs protected by 34 US patents Given below is the list of Heron Theraps Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11844837 Compositions of a polyorthoester and an organic acid excipient 21 Apr, 2036
Active
US10500208 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US10624850 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
Active
US10953018 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US11173118 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
Active
US11744800 Methods of use of emulsion formulations of an NK-1 receptor antagonist 18 Sep, 2035
Active
US11878074 Methods of use of emulsion formulations of an NK-1 receptor antagonist 18 Sep, 2035
Active
US9561229 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US9808465 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US9974742 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
Active
US9974793 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US9974794 Emulsion formulations of aprepitant 18 Sep, 2035
Active
US10098957 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US10213510 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US10632199 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US10898575 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US10980886 Compositions of a polyorthoester and an organic acid excipient 20 Apr, 2035
Active
US11083730 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US11083797 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US11413350 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US9694079 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US9801945 Long-acting polymeric delivery systems 20 Apr, 2035
Active
US10398686 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
Active
US11253504 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
Active
US9592227 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
Active
US9744163 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
Active
US9913909 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
Active
US10357570 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron 28 Sep, 2024 Expired
US8252304 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron 28 Sep, 2024 Expired
US8252305 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron 28 Sep, 2024 Expired
US8715710 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron 28 Sep, 2024 Expired
US9913910 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron 28 Sep, 2024 Expired
US6613355 Semi-solid delivery vehicle and pharmaceutical compositions 28 Jun, 2021 Expired
US6790458 Pharmaceutical compositions using semi-solid delivery vehicle 11 May, 2021 Expired


Given below is the list of recent legal activities going on the following drug patents of Heron Theraps Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 28 Feb, 2024 US8252305
Payment of Maintenance Fee, 12th Yr, Small Entity 28 Feb, 2024 US8252304
Mail Patent eCofC Notification 13 Feb, 2024 US11744800
Email Notification 13 Feb, 2024 US11744800
Recordation of Patent eCertificate of Correction 13 Feb, 2024 US11744800
Email Notification 13 Feb, 2024 US11744800
Mail Patent eCofC Notification 13 Feb, 2024 US11744800
Patent eCofC Notification 13 Feb, 2024 US11744800
Patent eCofC Notification 13 Feb, 2024 US11744800
Recordation of Patent eCertificate of Correction 13 Feb, 2024 US11744800
Mail Patent eGrant Notification 23 Jan, 2024 US11878074
Email Notification 23 Jan, 2024 US11878074
Patent eGrant Notification 23 Jan, 2024 US11878074
Recordation of Patent eGrant 23 Jan, 2024 US11878074
Patent Issue Date Used in PTA Calculation 23 Jan, 2024 US11878074


Heron Theraps Inc's Drug Patent Litigations

Heron Theraps Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 23, 2019, against patent number US10898575. The petitioner , challenged the validity of this patent, with Heron Therapeutics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Heron Theraps Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11083730 May, 2020 Decision
(19 Mar, 2021)
Heron Therapeutics, Inc.
US11083797 May, 2020 Decision
(19 Mar, 2021)
Heron Therapeutics, Inc.
US10898575 December, 2019 Decision
(02 Sep, 2020)
Heron Therapeutics, Inc.


Heron Theraps Inc's Family Patents

Heron Theraps Inc drugs have patent protection in a total of 20 countries. It's US patent count contributes only to 42.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Heron Theraps Inc Drug List

Given below is the complete list of Heron Theraps Inc's drugs and the patents protecting them.


1. Aponvie

Aponvie is protected by 11 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10500208 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US10624850 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US10953018 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US11173118 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US11744800 Methods of use of emulsion formulations of an NK-1 receptor antagonist 18 Sep, 2035
(10 years from now)
Active
US11878074 Methods of use of emulsion formulations of an NK-1 receptor antagonist 18 Sep, 2035
(10 years from now)
Active
US9561229 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9808465 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9974742 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US9974793 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9974794 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aponvie's drug page


2. Cinvanti

Cinvanti is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10500208 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US10624850 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US10953018 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US11173118 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US11744800 Methods of use of emulsion formulations of an NK-1 receptor antagonist 18 Sep, 2035
(10 years from now)
Active
US9561229 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9808465 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9974742 Emulsion formulations of an NK-1 receptor antagonist and uses thereof 18 Sep, 2035
(10 years from now)
Active
US9974793 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active
US9974794 Emulsion formulations of aprepitant 18 Sep, 2035
(10 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cinvanti's drug page


3. Sustol

Sustol is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10357570 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron 28 Sep, 2024
(7 days ago)
Expired
US8252304 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron 28 Sep, 2024
(7 days ago)
Expired
US8252305 Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron 28 Sep, 2024
(7 days ago)
Expired
US8715710 Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron 28 Sep, 2024
(7 days ago)
Expired
US9913910 Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron 28 Sep, 2024
(7 days ago)
Expired
US6613355 Semi-solid delivery vehicle and pharmaceutical compositions 28 Jun, 2021
(3 years ago)
Expired
US6790458 Pharmaceutical compositions using semi-solid delivery vehicle 11 May, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sustol's drug page


4. Zynrelef Kit

Zynrelef Kit is protected by 16 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11844837 Compositions of a polyorthoester and an organic acid excipient 21 Apr, 2036
(11 years from now)
Active
US10098957 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US10213510 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US10632199 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US10898575 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US10980886 Compositions of a polyorthoester and an organic acid excipient 20 Apr, 2035
(10 years from now)
Active
US11083730 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US11083797 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US11413350 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US9694079 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US9801945 Long-acting polymeric delivery systems 20 Apr, 2035
(10 years from now)
Active
US10398686 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
(9 years from now)
Active
US11253504 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
(9 years from now)
Active
US9592227 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
(9 years from now)
Active
US9744163 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
(9 years from now)
Active
US9913909 Compositions of a polyorthoester and an aprotic solvent 13 Mar, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zynrelef Kit's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List